Health Care Costs of Complex Perianal Fistula in Crohn’s Disease

2013 ◽  
Vol 58 (12) ◽  
pp. 3400-3406 ◽  
Author(s):  
M. Chaparro ◽  
C. Zanotti ◽  
P. Burgueño ◽  
I. Vera ◽  
F. Bermejo ◽  
...  
Keyword(s):  
Health Care ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Health Care Costs ◽  
Perianal Fistula ◽  
Care Costs

scholarly journals Health Care Costs and Resource Utilization Among Patients With Crohn’s Disease With and Without Perianal Fistula

2021 ◽  
Author(s):  
Grace Chen ◽  
Vasantha Pedarla ◽  
Kyle D Null ◽  
Susan E Cazzetta ◽  
Qasim Rana Khan ◽  
...  
Keyword(s):  
Health Care ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Resource Utilization ◽  
Health Care Costs ◽  
Perianal Fistula ◽  
The United States ◽  
The Us ◽  
Care Costs ◽  
Inpatient Length Of Stay

Abstract Background Perianal fistula (PAF), a complication of Crohn’s disease (CD), is associated with substantial economic costs and poor prognosis. We determined prevalence of PAF CD in the United States and compared costs and health care resource utilization (HRU) of PAF CD patients with matched non-PAF CD patients. Methods This was a retrospective cohort study of claims data from the IBM MarketScan Commercial Database from October 1, 2015, to September 30, 2018. Eligible patients were aged 18 to 89 years with ≥2 CD diagnoses. Patients with PAF CD had ≥1 PAF diagnosis or procedure code and were matched with non-PAF CD patients. Cumulative prevalence of PAF CD in the US population was calculated across total patients in MarketScan. All-cause and gastrointestinal (GI)-related costs and HRU were compared between groups using a generalized linear model (GLM). Results Cumulative 3-year prevalence of PAF was 7.70% of patients with CD (N = 81,862) and 0.01% of the US population. Among PAF CD (n = 1218) and matched non-PAF CD (n = 4095) patients, most all-cause costs and HRU were GI-related. Mean total all-cause and GI-related health care costs per patient and per year for PAF CD were $85,233 and $71,612, respectively, vs $40,526 and $29,458 for non-PAF CD (P < .0001). Among PAF CD vs non-PAF CD patients, GLM-adjusted proportions of patients with GI-related inpatient, outpatient, or pharmacy visits, mean GI-related inpatient length of stay, and mean GI-related surgeries were higher (P < .0001 for all comparisons). Conclusions Costs and HRU are significantly higher for patients with PAF CD vs non-PAF CD patients, highlighting the economic burden of the disease.

scholarly journals Direct Health Care Costs of Crohn's Disease and Ulcerative Colitis in US Children and Adults

2008 ◽  
Vol 135 (6) ◽  
pp. 1907-1913 ◽  
Author(s):  
Michael D. Kappelman ◽  
Sheryl L. Rifas–Shiman ◽  
Carol Q. Porter ◽  
Daniel A. Ollendorf ◽  
Robert S. Sandler ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Health Care ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Health Care Costs ◽  
Us Children ◽  
Care Costs

scholarly journals PGI12 HEALTH CARE COSTS RELATED TO THE TREATMENT OF CROHN'S DISEASE

2008 ◽  
Vol 11 (3) ◽  
pp. A87
Author(s):  
H Tian ◽  
J Marehbian ◽  
SL Hass ◽  
S Panjabi ◽  
HM Arrighi ◽  
...  
Keyword(s):  
Health Care ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Health Care Costs ◽  
Care Costs

S1201 Patient-Reported Utilization of Health Care Resources in Ulcerative Colitis and Crohn's Disease Matches Their Health Care Costs

2008 ◽  
Vol 134 (4) ◽  
pp. A-199-A-200
Author(s):  
Selwyn H. Odes ◽  
Hillel Vardi ◽  
Michael Friger ◽  
Pia S. Munkholm ◽  
Reinhold W. Stockbrugger ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Health Care ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Health Care Costs ◽  
Health Care Resources ◽  
Patient Reported ◽  
Care Costs

scholarly journals Health care costs by level of adherence for infliximab patients with crohn’s disease

2014 ◽  
Vol 17 (3) ◽  
pp. A39
Author(s):  
S. Michels ◽  
L. Ten Eyck ◽  
J. Vanderpoel ◽  
J. Lofland ◽  
M. Ingham ◽  
...  
Keyword(s):  
Health Care ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Health Care Costs ◽  
Care Costs

scholarly journals Health Care Resource Use and Costs for Crohn’s Disease before and after Infliximab Therapy

2011 ◽  
Vol 25 (9) ◽  
pp. 497-502 ◽  
Author(s):  
Dustin E Loomes ◽  
Christopher Teshima ◽  
Philip Jacobs ◽  
Richard Fedorak
Keyword(s):  
Health Care ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Health Care Costs ◽  
Resource Use ◽  
Health Care Resource ◽  
Infliximab Therapy ◽  
Economic Data ◽  
Before And After ◽  
Care Costs

BACKGROUND: Infliximab therapy in patients with Crohn’s disease decreases resource use; however, the overall impact on health-related expenditures is unclear, especially beyond one year of study.METHODS: A retrospective analysis of economic data one and two years before and after infliximab therapy was performed using patients who served as their own controls. Total health care resource use and direct health care costs were compared for patients with or without fistulae.RESULTS: Patients with one (n=66) and two (n=39) years of economic data before and after infliximab treatment had their resource use and direct health care costs estimated. In the year following initiation of infliximab therapy, there were significant decreases in health care use, reflected in total hospital days (495 to 155 [P<0.05]), inpatient colonoscopies (46 to 24 [P<0.05]), outpatient colonoscopies (58 to 33 [P<0.05]) and major surgeries (10 to 2 [P<0.05]). Direct health care costs of inpatient costs for luminal (−$1,747 [P<0.05]) and fistulizing disease (−$2,530 [P<0.05]), major surgeries (−$1240 [P<0.05]) and outpatient colonoscopies (−$184 [P<0.05]) were also significantly reduced before and after infliximab therapy. Total direct health care costs, including the drug cost of infliximab, increased ($21,416 [P<0.05]). In general, the trends in health care costs analyzed over four consecutive years paralleled the two consecutive-year analysis.CONCLUSIONS: Infliximab therapy in patients with Crohn’s disease resulted in a significant decrease in both resource use and health care costs, but an increase in total direct health care costs once the cost of infliximab was added.

Sign in / Sign up

Export Citation Format

Share Document